IRIS
FALASCA, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.738
AS - Asia 4.936
EU - Europa 4.648
SA - Sud America 823
Continente sconosciuto - Info sul continente non disponibili 802
AF - Africa 80
OC - Oceania 5
Totale 19.032
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.542
SG - Singapore 1.990
CN - Cina 1.244
IT - Italia 865
IE - Irlanda 679
BR - Brasile 635
RU - Federazione Russa 590
VN - Vietnam 546
SE - Svezia 531
UA - Ucraina 522
GB - Regno Unito 376
DE - Germania 373
TR - Turchia 369
FR - Francia 255
IN - India 212
FI - Finlandia 191
HK - Hong Kong 121
BD - Bangladesh 114
CA - Canada 97
KR - Corea 94
AR - Argentina 81
NL - Olanda 48
MX - Messico 46
AT - Austria 44
ID - Indonesia 38
PL - Polonia 34
JP - Giappone 32
EC - Ecuador 28
IQ - Iraq 28
ES - Italia 26
CO - Colombia 24
PK - Pakistan 23
ZA - Sudafrica 23
PH - Filippine 22
BE - Belgio 18
CZ - Repubblica Ceca 17
SA - Arabia Saudita 17
VE - Venezuela 17
RO - Romania 15
KE - Kenya 13
CH - Svizzera 12
LT - Lituania 12
PY - Paraguay 12
CL - Cile 9
EG - Egitto 9
JO - Giordania 9
NP - Nepal 9
TN - Tunisia 9
CR - Costa Rica 8
JM - Giamaica 8
PS - Palestinian Territory 8
UY - Uruguay 8
HN - Honduras 7
MA - Marocco 7
MY - Malesia 7
PE - Perù 7
UZ - Uzbekistan 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
IL - Israele 6
AU - Australia 5
AZ - Azerbaigian 5
DZ - Algeria 5
HR - Croazia 5
TW - Taiwan 5
CI - Costa d'Avorio 4
EE - Estonia 4
EU - Europa 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BB - Barbados 3
BY - Bielorussia 3
DK - Danimarca 3
GT - Guatemala 3
KW - Kuwait 3
KZ - Kazakistan 3
LB - Libano 3
LV - Lettonia 3
NG - Nigeria 3
PA - Panama 3
RS - Serbia 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BS - Bahamas 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
NI - Nicaragua 2
OM - Oman 2
PT - Portogallo 2
QA - Qatar 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BN - Brunei Darussalam 1
Totale 18.220
Salva come PNG Salva come JPEG
Città #
Singapore 1.472
San Jose 917
Chandler 780
Jacksonville 698
Dublin 662
Dallas 548
Ashburn 520
Princeton 319
Beijing 300
Council Bluffs 294
Southend 244
Nanjing 215
Izmir 195
Santa Clara 185
Ho Chi Minh City 169
The Dalles 166
Los Angeles 164
Altamura 141
Hanoi 135
Munich 126
Chieti 111
Dearborn 109
New York 108
Hong Kong 106
Wilmington 104
Cambridge 97
Ann Arbor 87
Tongling 82
Boardman 76
Buffalo 72
Columbus 70
São Paulo 70
Redondo Beach 69
Nanchang 65
Moscow 59
Pescara 58
Orem 48
Helsinki 46
Rome 43
Brooklyn 40
Milan 40
Nuremberg 38
Phoenix 38
Shenyang 37
Seattle 34
Turku 34
Pune 33
Washington 32
Denver 31
Tokyo 31
Dong Ket 30
Frankfurt am Main 30
Warsaw 30
Toronto 29
Tianjin 28
Chennai 27
Chicago 27
Haiphong 27
Hebei 27
Hefei 26
Atlanta 25
Jiaxing 25
Montreal 25
Rio de Janeiro 25
Da Nang 24
Kunming 24
Woodbridge 24
Hangzhou 22
Mexico City 22
London 21
Changsha 20
Manchester 20
Houston 19
Stockholm 19
Brussels 17
Mumbai 17
Brasília 16
Grevenbroich 16
Norwalk 16
San Francisco 16
Curitiba 15
Salvador 15
Baghdad 14
Jinan 14
Johannesburg 14
Vienna 14
Augusta 13
Boston 13
Changchun 13
Espoo 13
Jeddah 13
Hải Dương 12
Nairobi 12
Poplar 12
Brno 11
Shanghai 11
St Louis 11
Biên Hòa 10
Guangzhou 10
Guarulhos 10
Totale 11.062
Salva come PNG Salva come JPEG
Nome #
Effect of probiotic supplement on cytokine levels in HIV-infected individuals: A preliminary study 191
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C-virus infection and non-alcoholic fatty liver disease. 188
Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. 183
Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. 182
Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation 177
Air and surface measurements of SARS-CoV-2 inside a bus during normal operation 173
Atypical Sites of Lymphadenopathy after Anti-COVID-19 Vaccine: Ultrasound Features 171
Circulating CD40 ligand, Dickkopf-1 and P-selectin in HIV-infected patients 170
Study of immune alterations in patients with Chronic Fatigue Sindrome with different etiologies 169
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting 167
Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related 166
BNT162b2 mRNA vaccination leads to long-term protection from COVID-19 disease 166
Acute urinary retention due to HSV-1: a case report 161
Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. 155
Metabolic modifications in HIV-infected women 154
Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients 153
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 151
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 150
Cytomegalovirus infection in heart-transplants recipients, in a central region of Italy 150
The impact of homocysteine, B12, and D vitamins levels on functional neurocognitive performance in HIV-positive subjects 148
Canakinumab in a subgroup of patients with COVID-19 144
Dual nucleoside therapy for HIV infection: analysis of results and factors influencing viral response and long term efficacy 143
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 142
Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19 140
Could S-100b be a marker of the neurologic involvement in HIV-affected patients? 139
Cystatin C, adipokines and cardiovascular risk in HIV infected patients. 137
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 137
STUDIO CLINICO MULTICENTRICO PER LA VALUTAZIONE DELLA MICROALBUMINURIA NEI PAZIENTI CON INFEZIONE DA HIV 137
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 136
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 136
Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids 135
Relevance of plant lectins in human cell biology and immunology 133
Is the rate of virological failure to cART continuing to decline in recent calendar years? 132
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 131
Antiretroviral therapy management and rationalisation of available resources 130
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 130
Long term effect of telmisartan in HIV-positive male patients with high blood pressure 130
Quality of life, depression and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. 128
Cardiac Toxicity Associated with HCV Direct Antiviral Agents 128
Assessment of the Vanillin Anti-Inflammatory and Regenerative Potentials in Inflamed Primary Human Gingival Fibroblast 127
Treatment with silibyn- Vitamin E- Phospholipid complex in patients with Hepatitis C infection. 126
Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy 126
Beneficaial effects of telmisaratan in HIV+ diabetic insulin-dependent patient 125
Associations between immune depression and cardiovascular events in HIV infection. 125
Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV 125
Different strategies of 25OH vitamin D supplementation in HIV+ subjects. 124
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 124
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 124
New Therapeutic Options in Mild Moderate COVID-19 Outpatients 123
Interleukin-4 and interferon-gamma production during HIV-1 infection and changes induced by antiretroviral therapy. 123
Effetti del trattamento con vitamina e sulla sintomatologia muscoloscheletrica soggettiva ed oggettiva della sindrome da fatica cronica 123
Normal breathing releases SARS-CoV-2 into the air 123
Inguinal lymphadenopathy due to Bartonella henselae 122
Antimicrobial resistance in intensive care patients hospitalized with SEPSIS: a comparison between the COVID-19 pandemic and pre-pandemic era 121
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 121
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis 121
Clinical characteristics and cardiovascular implications of the dead patients for COVID-19 121
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study 120
Switch to rilpivirine improves diabetes in an elderly HIV-positive patient 120
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. 119
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 119
Short communication: Proangiogenic hematopoietic cells in acute HIV infection 118
High dose of erythropoietin in management of interferon/ribavirin induced anemia 117
IL-1beta induces alkaline phosphatase in human phagocytes 116
Periodontitis and cytokine patterns in HIV positive patients 116
Neuroprotective Potential of Bacopa monnieri: Modulation of Inflammatory Signals 116
Proteinuria in an African HIV-infected patient: effects of telmisartan. 115
Methicillin-resistant staphylococcus epidermidis (MRSE) endocarditis treated with linezolid 113
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. 113
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? 112
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 111
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART 111
Early detection of pleuro-pulmonary tuberculosis by bedside lung ultrasound: A case report and review of literature 110
Hypertension in HIV: Management and Treatment 110
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 110
Approach to COVID-19 in older adults and indications for improving the outcomes 110
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. 109
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 109
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 109
Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men 109
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014 109
The proinflammatory interleukin-21 elicits anti-tumor response and mediates autoimmunity 107
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 107
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. 107
First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 107
Evaluation of Cell Migration and Cytokines Expression Changes under the Radiofrequency Electromagnetic Field on Wound Healing In Vitro Model 107
Interleukin-31: a new cytokine involved in inflammation of the skin 106
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. 106
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study 106
Pidotimod and Immunological Activation in Individuals Infected with HIV 106
Circulating extracellular vesicles as new inflammation marker in hiv infection 105
Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. 105
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. 105
Increased production of oncostatin-M by lymphomononuclear cells from HIV-1-infected patients with neuroAIDS. 104
Infected atrial mixoma: a rare cause of fever 104
Severe HIV-associated hypertriglyceridemia treated with rosuvastatin plus mega-3 fatty acids 104
Correlation between neurocognitive disorders and pattern cytokines in HIV+ patients 104
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 104
Efficacy of canakinumab in mild or severe COVID-19 pneumonia 104
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. 103
Totale 12.839
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022722 0 0 11 157 46 17 30 57 57 28 80 239
2022/20232.316 208 360 139 241 205 439 131 174 252 27 67 73
2023/20241.157 76 50 84 42 100 326 262 58 9 19 12 119
2024/20252.970 187 528 383 112 60 134 97 183 267 209 336 474
2025/20266.810 470 251 876 897 590 370 1.115 405 670 646 363 157
2026/2027616 165 368 83 0 0 0 0 0 0 0 0 0
Totale 19.032